The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. SKB378/WIN378 produced significant and sustained effects on FEV1 (up to 174 mL mean increase, placebo-adjusted mean increases up to +256 mL, p=0.033), FeNO and blood eosinophils, key biomarkers that correlate with asthma exacerbati

Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth quarter of 2026 Financing led by RA Capital Management, joined by Canaan Partners, Forbion, and other investors Sept. 09, 2026 -- Solstice Oncology, a clinical-stage immuno-oncology company focused on treating c

Kura Oncology has spun out Caspian around KO-7246, which seeks to increase the number and activity of beta cells in the pancreas, in turn boosting insulin production in patients with diabetes. Caspian Therapeutics has arrived on the biopharma scene, bringing with it $50 million in starting funds, a potentially disease-modifying answer for diabetes and the backing of the industry’s biggest player in metabolic disease, Eli Lilly. Caspian was spun out from Kura Oncology specifically to advance an

Collaboration combines Rose Pharma investigational rapid-acting GLP-1 receptor agonist with MannKind’s Technosphere ® inhalation technology MannKind to receive an equity interest and potential royalties while providing pharmaceutical development and manufacturing support through completion of a Phase 1b clinical study Sept. 09, 2026 -- MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company focused on developing innovative, patient-centric therapies for chronic diseases, and Rose Pharm

Financing co-led by Alpha Wave and YK Bioventures, with participation from Eli Lilly and Company, Gaorong Ventures and existing investors ARCH Venture Partners, Khosla Ventures and Future Ventures Proceeds will advance Moonwalk's lead obesity program into the clinic and accelerate a pipeline of adipose-selective RNAi medicines targeting novel biology Dr. Stephen Djedjos appointed Senior Vice President, Clinical Development Moonwalk Biosciences , a biotechnology company developing first-in-class

– $50 million financing led by BVF Partners with participation from the T1D Fund, Invus, Montanova, Eli Lilly and Company, Kura Oncology, members of the Kura leadership team, and multiple, successful biotech entrepreneurs – – Preclinical studies with KO-7246 demonstrate selective expansion of pancreatic β cells, increased endogenous insulin production, and improved glycemic control across multiple models of Type 1 and Type 2 diabetes – – Preclinical data supporting KO-7246 selected for oral pres

The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. WIN378 produced significant and sustained effects on FEV1 (up to 174 mL mean increase, placebo-adjusted mean increases up to +256 mL, p=0.033), FeNO and blood eosinophils, key biomarkers that correlate with asthma exacerbations. Th

With $116 million in new funding on tap, BrainChild Bio said Tuesday that it has initiated a pivotal study of the B7-H3-targeted autologous CAR-T cell therapy BCB-276, in the hopes of delivering a much-needed new treatment option for patients with diffuse intrinsic pontine glioma (DIPG). With the current standard-of-care treatment for DIPG limited to palliative focal radiation therapy, median overall survival for this rare and aggressive paediatric brainstem tumour is about 11 months from diagn

Having recently secured FDA approval for the first in a new class of immunomodulatory drugs for multiple myeloma, Bristol Myers Squibb continues to make advances in the field, announcing Tuesday positive data from a registrational trial of its GPRC5D-directed CAR-T cell therapy arlocabtagene autoleucel (arlo-cel). The results come from the Phase II QUINTESSENTIAL study, which investigated arlo-cel in patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM). BMS note

Phase 3 study will evaluate safety and efficacy of an investigational once-daily formulation of trientine tetrahydrochloride compared to D-penicillamine as first line treatment in patients with Wilson disease. Sept. 8, 2026 -- Orphalan Inc. today announced the launch of the TRADITiONAL Study, a global, multicenter Phase 3 clinical trial evaluating an investigational once-daily formulation of trientine tetrahydrochloride for the first line treatment of individuals with Wilson disease. The study